Radius Health Inc (RDUS) Given Average Rating of “Hold” by Brokerages

Shares of Radius Health Inc (NASDAQ:RDUS) have earned an average rating of “Hold” from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $52.00.

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $58.00 price target on shares of Radius Health in a research report on Thursday. BidaskClub raised Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. Citigroup assumed coverage on Radius Health in a research report on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 price target on the stock. Finally, ValuEngine raised Radius Health from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st.

In other Radius Health news, VP Brent Hatzis-Schoch bought 1,778 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were acquired at an average price of $28.09 per share, with a total value of $49,944.02. Following the transaction, the vice president now owns 2,278 shares of the company’s stock, valued at $63,989.02. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Growth N. V. Biotech bought 50,000 shares of the business’s stock in a transaction dated Wednesday, October 25th. The shares were acquired at an average cost of $32.85 per share, for a total transaction of $1,642,500.00. Following the transaction, the insider now directly owns 5,548,799 shares in the company, valued at approximately $182,278,047.15. The disclosure for this purchase can be found here. Insiders have bought a total of 158,578 shares of company stock worth $4,659,916 in the last three months. Corporate insiders own 15.00% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new stake in shares of Radius Health during the 3rd quarter worth about $110,000. Ameritas Investment Partners Inc. raised its position in shares of Radius Health by 19.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 541 shares in the last quarter. Advisor Group Inc. raised its position in shares of Radius Health by 267.2% during the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 2,888 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Radius Health during the 2nd quarter worth about $211,000. Finally, Principal Financial Group Inc. raised its position in shares of Radius Health by 14.1% during the 2nd quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock worth $308,000 after acquiring an additional 839 shares in the last quarter.

Radius Health (NASDAQ:RDUS) opened at $36.12 on Friday. Radius Health has a twelve month low of $24.66 and a twelve month high of $49.16. The company has a market capitalization of $1,509.88, a PE ratio of -6.65 and a beta of 1.10. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The business had revenue of $13.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same quarter in the prior year, the company earned ($1.07) earnings per share. equities analysts anticipate that Radius Health will post -5.57 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Radius Health Inc (RDUS) Given Average Rating of “Hold” by Brokerages” was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.truebluetribune.com/2018/01/19/radius-health-inc-rdus-given-average-rating-of-hold-by-brokerages.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply